Garetosmab-grts (Pasatru; Regeneron Pharmaceuticals Inc.) for Fibrodysplasia Ossificans Progressiva

An intravenous fully human monoclonal antibody intended to reduce new heterotopic ossification and disease flare-ups in adults with fibrodysplasia ossificans progressiva.